Willemse Jeroen R J, Lahaye Max J, Goedegebuure Elisabeth P, Snaebjornsson Petur, Marchetti Serena, Vollebergh Marieke, van Golen Larissa W, Vogel Wouter V, Rostami Sajjad, Bodalal Zuhir, Beets-Tan Regina G H, Lambregts Doenja M J
Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
GROW Research Institute for Oncology & Reproduction - Maastricht University, Maastricht, The Netherlands.
Eur Radiol. 2025 May;35(5):2702-2711. doi: 10.1007/s00330-024-11149-w. Epub 2024 Oct 29.
This study aimed to evaluate the added benefit of body MRI (covering the chest, abdomen, and pelvis) to detect the primary tumour in patients with adenocarcinoma of unknown primary (ACUP) and a suspected abdominal malignancy in whom previous diagnostic work-up with CT and/or FDG-PET/CT did not yield a primary tumour diagnosis.
Thirty ACUP patients with a suspected primary tumour in the abdomen/pelvis (based on pathology and/or pattern of disease) underwent MRI (T2-weighted, DWI, pre- and post-contrast T1-weighted) after completion of their initial diagnostic work-up with CT and/or PET/CT. Effects of MRI to establish a primary tumour diagnosis (and to detect additional metastatic sites) were documented. Integration of all available imaging data, additional diagnostic procedures (e.g., endoscopy), histopathology, and whole genome sequencing served as the composite standard of reference.
MRI rendered a possible primary tumour diagnosis in 16/30 (53%) cases, which aligned with the final clinical diagnosis in 9/16 (56%) of these cases, thus resulting in a confirmed primary tumour diagnosis in 30% of our total patient cohort. These included four gastrointestinal, two hepatobiliary, one pancreatic, one ovarian and one breast cancer. MRI revealed extra metastatic sites in five patients (17%).
MRI can be of added value in the diagnostic work-up of ACUP patients with a suspected primary tumour originating from the abdomen or pelvis, in particular to detect gastrointestinal or hepatobiliary malignancies. Larger studies are needed to confirm these results and identify specific ACUP patients that are most likely to benefit from MRI.
Question Can body MRI help identify the primary tumour in patients with adenocarcinoma of unknown primary (ACUP)? Findings In this pilot of n = 30 ACUP patients with clinically suspected abdominal malignancies, body MRI was able to establish the primary tumour in 30% of cases. Clinical relevance Body MRI can be of added value (as an adjunct to CT and/or PET/CT) in the diagnostic work-up of ACUP patients with a suspected primary tumour originating from the abdomen or pelvis, especially to detect gastrointestinal or hepatobiliary malignancies.
本研究旨在评估体部磁共振成像(覆盖胸部、腹部和骨盆)对于检测原发性不明腺癌(ACUP)患者以及先前经CT和/或氟脱氧葡萄糖正电子发射断层显像/计算机断层扫描(FDG-PET/CT)诊断性检查未得出原发性肿瘤诊断结果的疑似腹部恶性肿瘤患者的原发性肿瘤的附加价值。
30例腹部/骨盆疑似原发性肿瘤的ACUP患者(基于病理学和/或疾病模式)在完成初始CT和/或PET/CT诊断性检查后接受了磁共振成像检查(T2加权成像、扩散加权成像、对比剂注射前后的T1加权成像)。记录了磁共振成像对于确立原发性肿瘤诊断(以及检测额外转移部位)的作用。整合所有可用的影像数据、额外的诊断程序(如内镜检查)、组织病理学和全基因组测序作为综合参考标准。
磁共振成像在16/30例(53%)病例中得出了可能的原发性肿瘤诊断,其中9/16例(56%)与最终临床诊断一致,从而在我们的全部患者队列中30%的患者确诊了原发性肿瘤。这些包括4例胃肠道癌、2例肝胆癌、1例胰腺癌、1例卵巢癌和1例乳腺癌。磁共振成像在5例患者(17%)中发现了额外的转移部位。
磁共振成像对于原发性不明且疑似原发性肿瘤源自腹部或骨盆的ACUP患者的诊断性检查可能具有附加价值,特别是用于检测胃肠道或肝胆恶性肿瘤。需要更大规模的研究来证实这些结果,并确定最有可能从磁共振成像中获益的特定ACUP患者。
问题 体部磁共振成像能否帮助识别原发性不明腺癌(ACUP)患者的原发性肿瘤?研究结果 在这项n = 30例临床疑似腹部恶性肿瘤的ACUP患者的试点研究中,体部磁共振成像在30%的病例中能够确立原发性肿瘤。临床意义 对于原发性不明且疑似原发性肿瘤源自腹部或骨盆的ACUP患者,体部磁共振成像(作为CT和/或PET/CT的辅助手段)在诊断性检查中可能具有附加价值,尤其是用于检测胃肠道或肝胆恶性肿瘤。